IN8BIO INC (INAB) Fundamental Analysis & Valuation

NASDAQ:INAB • US45674E2081

Current stock price

1.475 USD
+0.1 (+7.66%)
Last:

This INAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. INAB Profitability Analysis

1.1 Basic Checks

  • In the past year INAB has reported negative net income.
  • In the past year INAB has reported a negative cash flow from operations.
  • In the past 5 years INAB always reported negative net income.
  • INAB had a negative operating cash flow in each of the past 5 years.
INAB Yearly Net Income VS EBIT VS OCF VS FCFINAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • INAB has a Return On Assets (-60.22%) which is in line with its industry peers.
  • INAB has a Return On Equity (-70.54%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -60.22%
ROE -70.54%
ROIC N/A
ROA(3y)-98.19%
ROA(5y)-83.12%
ROE(3y)-133.7%
ROE(5y)-112.99%
ROIC(3y)N/A
ROIC(5y)N/A
INAB Yearly ROA, ROE, ROICINAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K 1.5K

1.3 Margins

  • INAB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INAB Yearly Profit, Operating, Gross MarginsINAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. INAB Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for INAB has been increased compared to 1 year ago.
  • The number of shares outstanding for INAB has been increased compared to 5 years ago.
  • Compared to 1 year ago, INAB has an improved debt to assets ratio.
INAB Yearly Shares OutstandingINAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
INAB Yearly Total Debt VS Total AssetsINAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

  • INAB has an Altman-Z score of -5.52. This is a bad value and indicates that INAB is not financially healthy and even has some risk of bankruptcy.
  • INAB has a worse Altman-Z score (-5.52) than 63.44% of its industry peers.
  • There is no outstanding debt for INAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.52
ROIC/WACCN/A
WACCN/A
INAB Yearly LT Debt VS Equity VS FCFINAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 8.82 indicates that INAB has no problem at all paying its short term obligations.
  • INAB's Current ratio of 8.82 is fine compared to the rest of the industry. INAB outperforms 75.63% of its industry peers.
  • A Quick Ratio of 8.82 indicates that INAB has no problem at all paying its short term obligations.
  • INAB has a Quick ratio of 8.82. This is in the better half of the industry: INAB outperforms 75.63% of its industry peers.
Industry RankSector Rank
Current Ratio 8.82
Quick Ratio 8.82
INAB Yearly Current Assets VS Current LiabilitesINAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. INAB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 73.33% over the past year.
EPS 1Y (TTM)73.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • INAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.14% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y62.19%
EPS Next 2Y25.44%
EPS Next 3Y37.52%
EPS Next 5Y13.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INAB Yearly Revenue VS EstimatesINAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
INAB Yearly EPS VS EstimatesINAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

1

4. INAB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for INAB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INAB Price Earnings VS Forward Price EarningsINAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INAB Per share dataINAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INAB's earnings are expected to grow with 37.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.44%
EPS Next 3Y37.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INAB Dividend Analysis

5.1 Amount

  • No dividends for INAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INAB Fundamentals: All Metrics, Ratios and Statistics

IN8BIO INC

NASDAQ:INAB (3/31/2026, 3:35:57 PM)

1.475

+0.1 (+7.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-01
Inst Owners33.06%
Inst Owner Change187.65%
Ins Owners10.54%
Ins Owner Change32.74%
Market Cap14.53M
Revenue(TTM)N/A
Net Income(TTM)-19.44M
Analysts82
Price Target6.46 (337.97%)
Short Float %2.04%
Short Ratio2.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.35%
Min EPS beat(2)28.46%
Max EPS beat(2)32.25%
EPS beat(4)3
Avg EPS beat(4)22.56%
Min EPS beat(4)-2.94%
Max EPS beat(4)32.46%
EPS beat(8)5
Avg EPS beat(8)15.59%
EPS beat(12)8
Avg EPS beat(12)9.04%
EPS beat(16)9
Avg EPS beat(16)3.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-87.27%
PT rev (3m)-87.14%
EPS NQ rev (1m)-146.87%
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.65%
EPS NY rev (3m)17.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-4.64
EYN/A
EPS(NY)-1.75
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS2.8
TBVpS2.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.22%
ROE -70.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.19%
ROA(5y)-83.12%
ROE(3y)-133.7%
ROE(5y)-112.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.82
Quick Ratio 8.82
Altman-Z -5.52
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.31%
Cap/Depr(5y)140.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y62.19%
EPS Next 2Y25.44%
EPS Next 3Y37.52%
EPS Next 5Y13.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-174.72%
EBIT Next 3Y-51.64%
EBIT Next 5Y0.96%
FCF growth 1Y47.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.36%
OCF growth 3YN/A
OCF growth 5YN/A

IN8BIO INC / INAB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IN8BIO INC (INAB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to INAB.


Can you provide the valuation status for IN8BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to IN8BIO INC (INAB). This can be considered as Overvalued.


What is the profitability of INAB stock?

IN8BIO INC (INAB) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for INAB stock?

The Earnings per Share (EPS) of IN8BIO INC (INAB) is expected to grow by 62.19% in the next year.